High materiality7/10
Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM) Post Release of Setmelanotide Data
Why it may matterVerify against the original reporting
Strong upside potential supported by data and reaffirmed rating.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Stifel Nicolaus reiterates Buy; target $133; posted price $94.73.
- Buy rating reaffirmed; target $133; price $94.73.
Key facts
- 01
Target: $133
- 02
Posted price: $94.73
- 03
Analyst firm: Stifel Nicolaus
- 04
Analyst: Paul Matteis
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.